AKER - エイカ―ズ・バイオサイエンス (Akers Biosciences Inc) エイカ―ズ・バイオサイエンス

 AKERのチャート


 AKERの企業情報

symbol AKER
会社名 Akers Biosciences Inc (エイカ―ズ・バイオサイエンス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Akers Biosciences Inc. develops manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company''s product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties including cardiology/emergency medicine metabolism/nutrition diabetes respiratory diseases and infectious diseases detection as well as for on and off-the-job alcohol safety initiatives. The Company''s primary focus is the development and sale of disposable diagnostic testing devices that can be performed in minutes to facilitate time sensitive therapeutic decisions. The Company''s main products include a disposable breathalyzer test that measures the blood alcohol content of the user a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.   エイカ―ズ・バイオサイエンスは米国の医療テスト製品メ―カ―。ポイント・オブ・ケアのスクリ―ニングやテスト製品の開発、製造を行う。主力製品は、血中アルコ―ル含有量の測定をする使い捨ての飲酒検査、人間の体内でフリ―ラジカル活性を測定する使い捨て飲酒検査、ヘパリンに対するアレルギ―反応を引き起こす抗体を検出する迅速試験など。   Akers Biosciences Inc mainly develops and manufactures rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner.
本社所在地 201 Grove Road Thorofare NJ 08086 USA
代表者氏名 Howard R. Yeaton ハワード・R・イートン
代表者役職名 Chief Executive Officer
電話番号 +1 856-848-8698
設立年月日 2005年
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 32人
url www.akersbio.com
nasdaq_url https://www.nasdaq.com/symbol/aker
adr_tso
EBITDA EBITDA(百万ドル) -8.19618
終値(lastsale) 0.3582
時価総額(marketcap) 33708873.7944
時価総額 時価総額(百万ドル) 33.31363
売上高 売上高(百万ドル) 2.44368
企業価値(EV) 企業価値(EV)(百万ドル) 25.06009
当期純利益 当期純利益(百万ドル) -9.12646
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Akers Biosciences Inc revenues decreased 52% to $829K. Net loss increased 81% to $3.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Administrative Expenses increase of 53% to $2.5M (expense) Research and Development Expenses - Rela increase from $23K to $54K (expense).

 AKERのテクニカル分析


 AKERのニュース

   Akers Biosciences reports FY results  2019-04-01
Akers Biosciences (NASDAQ: AKER ): FY GAAP EPS of -$0.99. More news on: Akers Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …
   Akers Biosciences reports FY results  2019-04-01
Akers Biosciences (NASDAQ: AKER ): FY GAAP EPS of -$0.99. More news on: Akers Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エイカ―ズ・バイオサイエンス AKER Akers Biosciences Inc)

 twitter  (公式ツイッターやCEOツイッターなど)